Avodart FDA Approval History: Complete Regulatory Timeline for Dutasteride

The Original 2001 FDA Approval: What NDA 021319 Established

The FDA granted approval for dutasteride 0.5 mg on November 20, 2001, under New Drug Application 021319. The approved indication was the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the need for BPH-related surgery. The full approval letter and original label are archived in the Drugs@FDA database.

The Key Phase III Program

Three key studies supported the initial NDA. The largest, a 2-year randomized controlled trial across 4,325 men, showed dutasteride reduced prostate volume by a mean of 25.7% versus a 1.4% increase in the placebo group. American Urological Association Symptom Score improved by 4.5 points with dutasteride versus 2.3 points with placebo at 24 months. These data are summarized in the FDA prescribing information and in the peer-reviewed literature indexed at PubMed.

Serum PSA fell by approximately 50% within 3 to 6 months of starting dutasteride, a pharmacodynamic effect the original label required clinicians to account for when interpreting PSA results. The FDA review team flagged this PSA suppression as a surveillance concern from the outset, requiring label language instructing prescribers to double the measured PSA to estimate true baseline. The FDA's CDER review documents detail this reasoning.

Mechanism Distinction From Finasteride

Dutasteride inhibits both type 1 and type 2 isoforms of 5-alpha reductase, suppressing serum dihydrotestosterone (DHT) by roughly 90% to 95% at the 0.5 mg daily dose. Finasteride inhibits only type 2 and reduces DHT by approximately 65% to 70%. This pharmacological distinction is documented in peer-reviewed pharmacology literature on PubMed. The dual-inhibition profile was central to GSK's differentiation argument in the NDA and remains clinically relevant when comparing class effects on sexual function and prostate cancer risk signaling.

2008 Label Update: Adding Combination Therapy Data

In 2008 the FDA approved a label supplement adding data from the CombAT (Combination of Avodart and Tamsulosin) trial, a 4-year double-blind study in 4,844 men. CombAT showed that the combination of dutasteride 0.5 mg and tamsulosin 0.4 mg daily reduced the relative risk of acute urinary retention or BPH-related surgery by 66% compared with tamsulosin monotherapy and by 19% compared with dutasteride monotherapy over 4 years. CombAT primary data are published and indexed at PubMed.

Jalyn: A Fixed-Dose Combination Product

Building on this supplement, the FDA approved Jalyn (dutasteride 0.5 mg / tamsulosin 0.4 mg) as a separate NDA on June 14, 2010. Jalyn carried the same BPH indication and the same emerging safety signals regarding cardiovascular risk and prostate cancer that were simultaneously under review in the REDUCE trial. The Jalyn approval record appears in the Drugs@FDA database.

2011 Label Update: The REDUCE Trial and High-Grade Prostate Cancer

This update is the most consequential change in dutasteride's regulatory history. The REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial enrolled 6,729 men aged 50 to 75 with PSA 2.5 to 10 ng/mL and a negative biopsy at baseline, randomized to dutasteride 0.5 mg or placebo for 4 years. The REDUCE primary publication appeared in the New England Journal of Medicine.

Key REDUCE Findings the FDA Cited

Dutasteride reduced the relative risk of prostate cancer detection on biopsy by 22.8% compared with placebo (19.9% vs. 25.1% cumulative incidence over 4 years, P<0.001). However, high-grade prostate cancers (Gleason score 8 to 10) were detected in 12 of 3,299 dutasteride patients versus 1 of 3,302 placebo patients over years 3 to 4 of the study. These data are cited directly in the FDA's 2011 safety communication and the revised label.

What the FDA Required in 2011

The FDA did not approve dutasteride for prostate cancer chemoprevention, explicitly rejecting that indication. The agency required the following label language: "5-alpha reductase inhibitors may increase the risk of high-grade prostate cancer." This wording applies to the entire 5-ARI class. The FDA's safety communication from June 9, 2011, specifies this language requirement.

The American Urological Association 2021 guidelines reflect this concern, stating: "Physicians should discuss the 7-year cumulative risk data from PCPT and the 4-year data from REDUCE when counseling patients who are candidates for 5-ARI therapy." The AUA BPH guideline is available through PubMed-indexed publications.

Clinical Decision Framework: PSA Monitoring Under 5-ARI Therapy

| Timepoint | Expected PSA change | Clinical action | |---|---|---| | Baseline (before starting) | Reference value | Perform digital rectal exam; document baseline | | 3 to 6 months | 40% to 50% decrease | Confirm suppression; "new baseline" = measured PSA x 2 | | Any confirmed rise >0.3 ng/mL above nadir | Unexpected | Evaluate for prostate cancer regardless of absolute value | | Annual thereafter | Stable or decreasing | Continue monitoring; any rise warrants urology referral |

Cardiovascular Safety Signals: Post-Market Surveillance

The CombAT 4-year data and subsequent post-market analyses raised a cardiovascular safety question that the FDA has tracked through its Sentinel system.

Heart Failure Signal From CombAT

In CombAT, cardiac failure was reported in 0.9% of combination-therapy patients versus 0.6% in the dutasteride monotherapy group and 0.5% in the tamsulosin group. The CombAT long-term safety analysis is indexed at PubMed. These absolute differences are small, but the FDA required label language noting the numerical imbalance.

Ongoing Pharmacovigilance

The FDA's Sentinel Active Surveillance Network has conducted ongoing monitoring of 5-ARI cardiovascular outcomes. Sentinel methodology and reports are accessible through the FDA's Sentinel program page. No definitive causal relationship between dutasteride monotherapy and serious cardiovascular events has been established in post-market data as of the most recent label revision, but prescribers are advised to use caution in men with known cardiac disease.

Sexual Adverse Effects: Label History and Post-Market Data

The original 2001 label documented decreased libido (3.0% vs. 1.7% placebo), erectile dysfunction (5.1% vs. 1.7% placebo), and ejaculation disorders (1.8% vs. 0.5% placebo) in the key trial population. These rates appear in the current FDA prescribing information, archived at Drugs@FDA.

Post-Finasteride Syndrome Discussion and 5-ARI Class

Post-market reports of persistent sexual dysfunction after stopping 5-ARIs have generated regulatory attention for the class, primarily for finasteride. A 2012 FDA label update for finasteride 1 mg (Propecia) added language about persistent sexual side effects; the Avodart label was subsequently reviewed for analogous signals. The current Avodart label includes language on persistence of sexual adverse events after discontinuation in a subset of patients. Prescribers should document baseline sexual function before starting therapy.

Gynecomastia Reports

Breast disorders, including gynecomastia and breast tenderness, were reported at a rate of approximately 1.3% in dutasteride-treated men versus 0.5% in placebo-treated men across the key trials. These data are included in the adverse reactions section of the prescribing information. Patients should be counseled to report breast lumps or nipple discharge, given the theoretical concern about male breast cancer in the context of altered androgen/estrogen balance.

Off-Label Uses: Hair Loss and What Regulatory Approval Covers

Dutasteride is not FDA-approved for androgenetic alopecia in the United States. This is a frequently misunderstood point. The South Korean Ministry of Food and Drug Safety approved dutasteride 0.5 mg for male-pattern hair loss in 2009, and Japan followed in 2015, but the FDA has not granted this indication.

Evidence Supporting Off-Label Hair Loss Use

Eun et al. (J Am Acad Dermatol 2010, N=153) demonstrated that dutasteride 0.5 mg daily produced statistically greater improvement in hair count and investigator assessments versus finasteride 1 mg and placebo at 24 weeks, with P<0.001 for between-group comparisons. The Eun et al. Study is indexed at PubMed. A randomized dose-ranging trial published in the Journal of the American Academy of Dermatology showed dose-dependent improvements in target area hair count across dutasteride doses of 0.05 mg, 0.1 mg, 0.5 mg, and 2.5 mg versus placebo. This dose-ranging study is available at PubMed.

Regulatory Status for Hair Loss

Because dutasteride carries no FDA hair-loss approval, prescribers who use it for androgenetic alopecia are doing so off-label. Informed consent documentation should reflect this. The FDA's current stance has not changed since the original 2001 approval; no NDA supplement for alopecia has been filed or approved for the U.S. Market as of mid-2025. FDA drug database records confirm the current approved indications.

Pregnancy Category X and Teratogenicity: A Critical Safety Warning

Dutasteride is Pregnancy Category X. Animal studies at doses producing exposures similar to human therapeutic doses showed feminization of male rat fetuses, including hypospadias and underdeveloped external genitalia. Reproductive toxicology data are summarized in the FDA prescribing information. Human exposure risk is real: dutasteride is absorbed through skin, so women who are or may become pregnant must not handle broken or crushed capsules.

Blood Donation Restriction

The FDA label requires that men taking dutasteride not donate blood during treatment and for 6 months after discontinuation, specifically to prevent inadvertent exposure to a pregnant female blood transfusion recipient. This 6-month window reflects dutasteride's approximately 5-week half-life (roughly 4 to 5 half-lives for near-complete elimination). The blood donation restriction is stated in the current prescribing information on Drugs@FDA.

Generic Approval History and Current Market Status

The FDA approved the first generic dutasteride 0.5 mg soft-gel capsules in 2015, when GSK's data exclusivity and patent protections expired. Multiple abbreviated new drug applications (ANDAs) are now active. The Orange Book entry for dutasteride lists currently approved products with patent and exclusivity expiration data.

Bioequivalence Requirements for Soft-Gel Capsules

Generic dutasteride manufacturers must demonstrate bioequivalence to Avodart using a standard fed-state pharmacokinetic study design, given that the soft-gel formulation is susceptible to food-effect variation. The FDA's guidance on bioequivalence for modified-release and lipophilic formulations applies. FDA bioequivalence guidance documents are available through the FDA guidance portal. Clinicians switching patients between branded and generic dutasteride should expect pharmacokinetically equivalent exposure, though formulation excipients vary by manufacturer.

EMA Regulatory Status and International Context

The European Medicines Agency (EMA) approved dutasteride (Avodart) for BPH in 2002, one year after the FDA. The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a European Public Assessment Report (EPAR) that mirrors the FDA's safety profile conclusions, including the high-grade prostate cancer risk language added after the REDUCE trial. The EMA EPAR for Avodart is accessible through the EMA's product database. Health Canada approved dutasteride in 2003 under the brand name Avodart, with label language closely tracking the FDA and EMA documents.

Current Prescribing Information: Key Label Sections Summarized

Contraindications

The current FDA label lists two contraindications: known hypersensitivity to dutasteride, other 5-ARIs, or any component of the capsule; and use by women or children. Current label text is available at Drugs@FDA.

Drug Interactions

Dutasteride is metabolized primarily by CYP3A4 and to a lesser extent CYP3A5. Co-administration with potent CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, or ciprofloxacin may increase dutasteride blood concentrations. The pharmacokinetic interaction data are described in Section 12 of the prescribing information. No dose adjustment recommendation exists in the current label, but clinicians should monitor patients on potent CYP3A4 inhibitors for increased adverse effects.

PSA Monitoring Protocol

The FDA label requires that any confirmed increase in PSA while on dutasteride be evaluated, even if the new PSA value is still within the normal range. The label states: "To interpret an isolated PSA value in a man treated with dutasteride for six months or more, the measured PSA value should be doubled for comparison with normal values in untreated men." This language has been in place since the 2001 approval and was reinforced by the 2011 REDUCE-driven update. The full prescribing information text is accessible at Drugs@FDA.

Regulatory Timeline: Year-by-Year Summary

| Year | Regulatory event | |---|---| | 2001 | FDA approves Avodart (NDA 021319) for symptomatic BPH | | 2002 | EMA approval; GSK launches in European markets | | 2003 | Health Canada approval | | 2008 | FDA label supplement adds CombAT combination-therapy data | | 2009 | South Korea approves dutasteride 0.5 mg for male-pattern hair loss | | 2010 | FDA approves Jalyn (dutasteride/tamsulosin fixed-dose combination) | | 2011 | FDA requires class-wide high-grade prostate cancer label update; chemoprevention indication rejected | | 2012 | FDA adds cardiovascular imbalance data from CombAT to label | | 2015 | First generic dutasteride ANDAs approved in the U.S. | | 2015 | Japan approves dutasteride for androgenetic alopecia | | 2025 | Multiple generics available; no new NDA supplements for alopecia in the U.S. |